Royal Emerald Pharma's Bid for Big-Time Marijuana Brewing
Published Date: 3/27/2025
Notice
Summary
Royal Emerald Pharmaceuticals wants to become a big-time maker of marijuana and related substances for research and medicine. If you’re a registered manufacturer or just interested, you can share your thoughts or ask for a hearing by May 27, 2025. This move could boost the supply of marijuana-based ingredients for science and medicine, with no extra costs announced yet.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Royal Emerald seeks bulk marijuana registration
On February 25, 2025, Royal Emerald Pharmaceuticals applied to be registered as a bulk manufacturer of Marihuana Extract (code 7350), Marihuana (code 7360), and Tetrahydrocannabinols (code 7370), all listed in Schedule I. The company plans to bulk manufacture those substances to provide Cannabis as botanical raw material and/or active pharmaceutical ingredients (API) to Drug Enforcement Administration-registered researchers and manufacturers. Comments or requests for a hearing on the application must be submitted by May 27, 2025, and the registration would authorize only the listed bulk-manufacture activities for those drug codes.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
2026-20553, Decision and Order: Medpharm Research, LLC
Medpharm Research, LLC wanted to get official permission to make marijuana in bulk, but the DEA said no. The DEA found that Medpharm’s related companies were handling marijuana without permission and even selling it for recreational use, which breaks the rules. So, Medpharm’s application was denied, and they can’t legally manufacture marijuana in bulk now.
Previous / Next Documents
Previous: 2025-05278, Importer of Controlled Substances Application: SpecGx LLC
SpecGx LLC wants to become an official importer of some strong controlled substances like phenylacetone, coca leaves, and thebaine. This affects companies and people involved in handling these drugs, who can share their thoughts or ask for a hearing by April 28, 2025. No direct money changes yet, but this move could shake up the drug import scene soon!
Next: 2025-05280, Importer of Controlled Substances Application: Patheon API Services, Inc.
Patheon API Services, Inc. wants to become an official importer of some powerful controlled substances like dimethyltryptamine and psilocybin. People and companies involved with these drugs can share their thoughts or ask for a hearing by April 28, 2025. This move could impact how these substances are brought into the U.S., but no costs or fees are mentioned yet.